CryoLife Enhances Management Team with Promotions
ATLANTA, Jan. 4, 2012 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that it has promoted David C. Gale, Ph.D., to the position of Vice President, Research and Development; and David P. Lang to the newly created position of Vice President, Market Development Surgical Adhesives and Starch Medical Relations. Dr. Gale will report to Steven G. Anderson, President and Chief Executive Officer and Mr. Lang will report to Gerald B. Seery, Senior Vice President, Sales and Marketing.
"We are extremely pleased to make these significant additions to our leadership team," said Steven G. Anderson, President and Chief Executive Officer. "Dr. David Gale brings more than 15 years of research and development experience, holding over 30 issued U.S. patents covering material, processing and designs of medical devices. We will continue to call upon his wealth of experience as he oversees the important activities supporting the advancement of our product pipeline, which includes new products in both our core tissue processing segment and within our higher growth, higher margin medical devices segment."
Mr. Anderson added, "David Lang brings 35 years of marketing and business development experience in the medical device industry. He will continue to play a critical role in the growth of BioGlue, BioFoam and PerClot, particularly as we work to gain and leverage new regulatory approvals for these products."
David C. Gale, Ph.D. joined CryoLife in 2009 as Senior Director of Research and Development. Prior to joining CryoLife, he was Vice President, Research and Development of Sinexus Inc., a manufacturer of drug-eluting (or releasing) stents located in Palo Alto, California. He previously worked in research and development of bioabsorbable polymers and stents at Abbott Laboratories and Birmingham Polymers. David Gale has a B